Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-Derived Exosomes in Progressive MS
NCT07146087Phase 1Suspended
- Sponsor
- Biocells Medical
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing MSC-Derived Exosomes with Placebo (2 arms). Primary endpoint: Change in Expanded Disability Status Scale score at 24 months. Started Jul 2020; status: suspended.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07146087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146087.